480450-71-3 Usage
Description
Thiazolo[5,4-c]pyridine-2-carboxamide, N-[(1R,2S,5S)-2-amino-5-[(dimethylamino)carbonyl]cyclohexyl]-4,5,6,7-tetrahydro-5-methylis a complex organic compound with a unique chemical structure. It is characterized by its thiazolo[5,4-c]pyridine-2-carboxamide core, which is fused with a cyclohexyl ring. The molecule also contains an amino group, a dimethylaminocarbonyl group, and a methyl group. Thiazolo[5,4-c]pyridine-2-carboxamide,
N-[(1R,2S,5S)-2-amino-5-[(dimethylamino)carbonyl]cyclohexyl]-4,5,6,7-
tetrahydro-5-methylis an impurity of Edoxaban (E555520), which is an anticoagulant drug.
Uses
1. Pharmaceutical Industry:
Thiazolo[5,4-c]pyridine-2-carboxamide, N-[(1R,2S,5S)-2-amino-5-[(dimethylamino)carbonyl]cyclohexyl]-4,5,6,7-tetrahydro-5-methylis used as an impurity in the production of Edoxaban (E555520), an anticoagulant drug. Edoxaban acts as a direct factor Xa inhibitor, playing a crucial role in the prevention and treatment of blood clot-related disorders.
2. Research and Development:
Thiazolo[5,4-c]pyridine-2-carboxamide,
N-[(1R,2S,5S)-2-amino-5-[(dimethylamino)carbonyl]cyclohexyl]-4,5,6,7-
tetrahydro-5-methylmay also be used in research and development for the discovery of new pharmaceuticals and therapeutic agents. Its unique chemical structure and properties can provide valuable insights into the design and synthesis of novel drugs targeting various diseases and conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 480450-71-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,8,0,4,5 and 0 respectively; the second part has 2 digits, 7 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 480450-71:
(8*4)+(7*8)+(6*0)+(5*4)+(4*5)+(3*0)+(2*7)+(1*1)=143
143 % 10 = 3
So 480450-71-3 is a valid CAS Registry Number.
480450-71-3Relevant articles and documents
Processes for the Preparation of Edoxaban and Intermediates Thereof
-
, (2018/07/15)
The present invention provides processes for the preparation of Edoxaban (1) and salts thereof, as well as intermediates thereof. In particular, intermediate compounds and/or salts of the Formulae (3), (4), (6-A), (7-A), (8-A), (9-A) and (10-AS) are provided.
Diamine derivatives
-
, (2008/06/13)
A compound represented by the general formula (1): Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4??(1) wherein R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like; Q2 is a single bond or the like; Q3 is a group in which Q5 is an alkylene group having 1 to 8 carbon atoms, or the like; and T0 and T1 are carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.